Kasper Rossing

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/12082968/publications.pdf

Version: 2024-02-01

56 papers	4,389 citations	172386 29 h-index	168321 53 g-index
56 all docs	56 docs citations	56 times ranked	3571 citing authors

#	Article	IF	Citations
1	Prognostic value of myocardial flow reserve obtained by 82-rubidium positron emission tomography in long-term follow-up after heart transplantation. Journal of Nuclear Cardiology, 2022, 29, 2555-2567.	1.4	4
2	Oxygen Uptake During Activities of Daily Life in Patients Treated With a Left Ventricular Assist Device. Journal of Heart and Lung Transplantation, 2022, 41, 982-990.	0.3	4
3	Three decades of heart transplantation: experience and long-term outcome. Scandinavian Cardiovascular Journal, 2022, 56, 65-72.	0.4	1
4	Long-term prognosis following hospitalization for acute myocarditis â€“ a matched nationwide cohort study. Scandinavian Cardiovascular Journal, 2021, 55, 264-269.	0.4	6
5	Cardiac arrest in anti-mitochondrial antibody associated inflammatory myopathy. Oxford Medical Case Reports, 2021, 2021, omaa150.	0.2	6
6	Urinary peptides in heart failure: a link to molecular pathophysiology. European Journal of Heart Failure, 2021, 23, 1875-1887.	2.9	37
7	Reassessment of Gene-Elusive Familial Dilated Cardiomyopathy Leading to the Discovery of a Homozygous AARS2 Variantâ€"The Importance of Regular Reassessment of Genetic Findings. Neurology International, 2021, 11, 122-128.	0.2	0
8	Socioeconomic Disparities in Referral for Invasive Hemodynamic Evaluation for Advanced Heart Failure: A Nationwide Cohort Study. Circulation: Heart Failure, 2021, 14, e008662.	1.6	10
9	Computed Tomographyâ€"Estimated Right Ventricular Function and Exercise Capacity in Patients with Continuous-Flow Left Ventricular Assist Devices. ASAIO Journal, 2020, 66, 8-16.	0.9	12
10	Intravascular ultrasoundâ€"guided selection for early noninvasive cardiac allograft vasculopathy screening in heart transplant recipients. Clinical Transplantation, 2020, 34, e14124.	0.8	7
11	Pulmonary artery pressure as a method for assessing hydration status in an anuric hemodialysis patient â€“ a case report. BMC Nephrology, 2020, 21, 266.	0.8	1
12	Clinical presentation and outcomes in women and men with advanced heart failure. Scandinavian Cardiovascular Journal, 2020, 54, 361-368.	0.4	4
13	Long-Term Adverse Cardiac Outcomes in Patients With Sarcoidosis. Journal of the American College of Cardiology, 2020, 76, 767-777.	1.2	61
14	Plasma Somatostatin in Advanced Heart Failure: Association with Cardiac Filling Pressures and Outcome. Cardiology, 2020, 145, 769-778.	0.6	3
15	Relationship between invasive hemodynamics and liver function in advanced heart failure. Scandinavian Cardiovascular Journal, 2019, 53, 235-246.	0.4	4
16	Lung diffusion capacity in advanced heart failure: relation to central haemodynamics and outcome. ESC Heart Failure, 2019, 6, 379-387.	1.4	15
17	Medical and mechanical unloading in advanced heart failure: hope for cardiac recovery?. European Journal of Heart Failure, 2018, 20, 175-177.	2.9	1
18	Copeptin levels and invasive hemodynamics in patients with advanced heart failure. Biomarkers in Medicine, 2018, 12, 861-870.	0.6	3

#	Article	IF	Citations
19	Influence of renal impairment on aldosterone status, calcium metabolism, and vasopressin activity in outpatients with systolic heart failure. ESC Heart Failure, 2017, 4, 554-562.	1.4	4
20	Classification of Death Causes after Transplantation (CLASS): Evaluation of Methodology and Initial Results. Open Forum Infectious Diseases, 2017, 4, S703-S703.	0.4	0
21	Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus. Journal of Translational Medicine, 2016, 14, 203.	1.8	17
22	Urinary Proteomics Pilot Study for Biomarker Discovery and Diagnosis in Heart Failure with Reduced Ejection Fraction. PLoS ONE, 2016, 11, e0157167.	1.1	42
23	Outcomes and hospital admissions during long-term support with a HeartMate II. Scandinavian Cardiovascular Journal, 2015, 49, 367-75.	0.4	6
24	Influence of renal impairment on myocardial function in outpatients with systolic heart failure: An echocardiographic and cardiac biomarker study. International Journal of Cardiology, 2014, 177, 942-948.	0.8	6
25	Effect of increasing pump speed during exercise on peak oxygen uptake in heart failure patients supported with a continuousâ€flow left ventricular assist device. A doubleâ€blind randomized study. European Journal of Heart Failure, 2014, 16, 403-408.	2.9	74
26	Improved Survival and Renal Prognosis of Patients With Type 2 Diabetes and Nephropathy With Improved Control of Risk Factors. Diabetes Care, 2014, 37, 1660-1667.	4.3	68
27	Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: A long term follow-up study. International Journal of Cardiology, 2013, 170, 202-207.	0.8	32
28	Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2013, 14, 161-166.	1.0	21
29	The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP. Scandinavian Journal of Clinical and Laboratory Investigation, 2012, 72, 137-142.	0.6	18
30	Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria. Amino Acids, 2012, 42, 1627-1639.	1.2	22
31	Multicentric Validation of Proteomic Biomarkers in Urine Specific for Diabetic Nephropathy. PLoS ONE, 2010, 5, e13421.	1.1	117
32	Naturally Occurring Human Urinary Peptides for Use in Diagnosis of Chronic Kidney Disease. Molecular and Cellular Proteomics, 2010, 9, 2424-2437.	2.5	434
33	Urinary Collagen Fragments Are Significantly Altered in Diabetes: A Link to Pathophysiology. PLoS ONE, 2010, 5, e13051.	1.1	51
34	Quantitative Urinary Proteome Analysis for Biomarker Evaluation in Chronic Kidney Disease. Journal of Proteome Research, 2009, 8, 268-281.	1.8	221
35	The urinary proteome in diabetes and diabetesâ€associated complications: New ways to assess disease progression and evaluate therapy. Proteomics - Clinical Applications, 2008, 2, 997-1007.	0.8	64
36	CEâ€MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics - Clinical Applications, 2008, 2, 964-973.	0.8	178

#	Article	IF	Citations
37	Urinary Proteomics in Diabetes and CKD. Journal of the American Society of Nephrology: JASN, 2008, 19, 1283-1290.	3.0	267
38	Clinical proteomics: A need to define the field and to begin to set adequate standards. Proteomics - Clinical Applications, 2007, 1, 148-156.	0.8	274
39	Impact of diabetic nephropathy and angiotensin II receptor blockade on urinary polypeptide patterns. Kidney International, 2005, 68, 193-205.	2.6	126
40	Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney International, 2005, 68, 1190-1198.	2.6	196
41	Beneficial impact of spironolactone in diabetic nephropathy. Kidney International, 2005, 68, 2829-2836.	2.6	201
42	Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy: A randomized, double-masked, cross-over study. Diabetes Care, 2005, 28, 2106-2112.	4.3	266
43	Progression of nephropathy in type 2 diabetic patients. Kidney International, 2004, 66, 1596-1605.	2.6	270
44	Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points. Seminars in Nephrology, 2004, 24, 147-157.	0.6	57
45	Single versus dual blockade of the renin-angiotensin system (angiotensin-converting enzyme) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Nephrology and Hypertension, 2004, 13, 319-324.	1.0	23
46	Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy. Kidney International, 2003, 63, 1874-1880.	2.6	205
47	Comparative Effects of Irbesartan on Ambulatory and Office Blood Pressure: A substudy of ambulatory blood pressure from the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study. Diabetes Care, 2003, 26, 569-574.	4.3	30
48	Renoprotective Effects of Adding Angiotensin II Receptor Blocker to Maximal Recommended Doses of ACE Inhibitor in Diabetic Nephropathy: A randomized double-blind crossover trial. Diabetes Care, 2003, 26, 2268-2274.	4.3	222
49	Optimal Dose of Candesartan for Renoprotection in Type 2 Diabetic Patients With Nephropathy: A double-blind randomized cross-over study. Diabetes Care, 2003, 26, 150-155.	4.3	73
50	Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy. Nephrology Dialysis Transplantation, 2002, 17, 1019-1024.	0.4	112
51	Dual Blockade of the Renin-Angiotensin System in Diabetic Nephropathy: A randomized double-blind crossover study. Diabetes Care, 2002, 25, 95-100.	4.3	200
52	Evolving strategies for renoprotection: diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2001, 10, 515-522.	1.0	76
53	Progression of diabetic nephropathy in normotensive type 1 diabetic patients. Kidney International, 1999, 56, S101-S105.	2.6	80
54	Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy. Kidney International, 1998, 53, 1002-1006.	2.6	91

#	Article	IF	Citations
55	Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy. Kidney International, 1996, 49, 1778-1782.	2.6	63
56	Aortic Pulsatility Index: A New Haemodynamic Measure with Prognostic Value in Advanced Heart Failure. Cardiac Failure Review, 0, 8, .	1.2	3